Anti-glypican-1 antibody–drug conjugate is a potential therapy against pancreatic cancer

BACKGROUND: Pancreatic cancer (PDAC) is the most lethal malignancy. New treatment options for it are urgently required. The aim was to develop an antibody–drug conjugate (ADC) targeting glypican-1 (GPC-1) as a new therapy for PDAC. METHODS: We evaluated GPC-1 expression in resected PDAC specimens an...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishigaki, Takahiko, Takahashi, Tsuyoshi, Serada, Satoshi, Fujimoto, Minoru, Ohkawara, Tomoharu, Hara, Hisashi, Sugase, Takahito, Otsuru, Toru, Saito, Yurina, Tsujii, Shigehiro, Nomura, Taisei, Tanaka, Koji, Miyazaki, Yasuhiro, Makino, Tomoki, Kurokawa, Yukinori, Nakajima, Kiyokazu, Eguchi, Hidetoshi, Yamasaki, Makoto, Mori, Masaki, Doki, Yuichiro, Naka, Tetsuji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7189381/
https://www.ncbi.nlm.nih.gov/pubmed/32152502
http://dx.doi.org/10.1038/s41416-020-0781-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7189381/
https://www.ncbi.nlm.nih.gov/pubmed/32152502
http://dx.doi.org/10.1038/s41416-020-0781-2

Ejemplares similares